Effects of the kinase inhibitor sorafenib on heart, muscle, liver and plasma metabolism in vivo using non-targeted metabolomics analysis

What is it about?

New effective chemotherapeutic agents to treat cancers have been introduced recently, including the drug sorafenib for advanced renal cell cancer, hepatocellular (liver) carcinoma, and thyroid cancer. The cellular targets of these chemotherapeutic agents can affect both cancerous and non-cancerous tissues throughout the body. Understanding these effects on the heart are critical given the high prevalence of cardiovascular disease. We show for the first time the specific metabolic alterations that are found in the heart, skeletal muscle, liver, and plasma in the presence of a physiological cardiac defect.

Featured Image